ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a sell rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

A number of other equities research analysts have also recently commented on PRQR. BidaskClub upgraded Misonix from a buy rating to a strong-buy rating in a research report on Wednesday, July 3rd. ValuEngine cut Welbilt from a hold rating to a sell rating in a report on Wednesday, June 12th. Finally, Chardan Capital lifted their price objective on Krystal Biotech from $50.00 to $57.50 and gave the stock a buy rating in a report on Tuesday, March 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $28.67.

NASDAQ:PRQR opened at $9.07 on Wednesday. ProQR Therapeutics has a 52 week low of $6.40 and a 52 week high of $24.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.08 and a current ratio of 10.08. The company’s 50-day simple moving average is $10.58.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.05). As a group, analysts expect that ProQR Therapeutics will post -1.65 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of PRQR. BlackRock Inc. acquired a new stake in ProQR Therapeutics in the 4th quarter worth about $11,064,000. Hsbc Holdings PLC purchased a new position in ProQR Therapeutics in the 4th quarter worth approximately $7,890,000. Nikko Asset Management Americas Inc. purchased a new position in ProQR Therapeutics in the 1st quarter worth approximately $4,016,000. FMR LLC lifted its stake in ProQR Therapeutics by 27.8% in the 4th quarter. FMR LLC now owns 1,081,366 shares of the biopharmaceutical company’s stock worth $17,064,000 after purchasing an additional 235,053 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in ProQR Therapeutics in the 4th quarter worth approximately $1,428,000. Institutional investors own 61.75% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Recommended Story: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on ProQR Therapeutics (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.